Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates (Q37755154)

From Wikidata

Jump to navigation Jump to search

scientific article published on April 2009

Language	Label	Description	Also known as
English	Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates	scientific article published on April 2009

Statements

scholarly article

1 reference

Europe PubMed Central

22 August 2017

Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates (English)

1 reference

Europe PubMed Central

22 August 2017

0 references

author name string

Mai Yamauchi

1

1 reference

Europe PubMed Central

22 August 2017

Noriko Gotoh

2

1 reference

Europe PubMed Central

22 August 2017

publication date

1 April 2009

1 reference

Europe PubMed Central

22 August 2017

Biomarkers in Medicine

1 reference

Europe PubMed Central

22 August 2017

3

1 reference

Europe PubMed Central

22 August 2017

2

1 reference

Europe PubMed Central

22 August 2017

139-151

1 reference

Europe PubMed Central

22 August 2017

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

HER1/EGFR targeting: refining the strategy

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Structure of the extracellular region of HER3 reveals an interdomain tether

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

EGF-ERBB signalling: towards the systems level

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Predictors of the response to gefitinib in refractory non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

EGFR mutation is specific for terminal respiratory unit type adenocarcinoma

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

A curious link between epidermal growth factor receptor amplification and survival: effect of "allele dilution" on gefitinib sensitivity?

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

EGFR and erbB2 mutation status in Japanese lung cancer patients

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Exploiting the PI3K/AKT pathway for cancer drug discovery

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Somatic mutations of the ERBB4 kinase domain in human cancers

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Somatic mutations affect key pathways in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Uncommon V599E BRAF mutations in Japanese patients with lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Genetic predictors of MEK dependence in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

EGFR exon 20 insertion mutation in Japanese lung cancer.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Activation of tyrosine kinases by mutation of the gatekeeper threonine

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

The biology and clinical relevance of the PTEN tumor suppressor pathway

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

1 reference

https://api.crossref.org/works/10.2217%2FBMM.09.9

21 January 2018

Identifiers

10.2217/BMM.09.9

1 reference

Europe PubMed Central

22 August 2017

release_jqba7p5vwfalzgu3q4hj35sdle

1 reference

https://api.fatcat.wiki/v0/release/jqba7p5vwfalzgu3q4hj35sdle

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

22 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37755154&oldid=1837362348"